This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Molecular Tumor Board Series II: Colon Adenocarcinoma, Endometrial Adenocarcinoma and Breast Invasive Ductal Carcinoma (IDC)

Molecular Tumor Board Series II: Colon Adenocarcinoma, Endometrial Adenocarcinoma and Breast Invasive Ductal Carcinoma (IDC)

Format

Patient Case Study

Time to Complete

45 minutes (3 15-minute modules)

Released

February 22, 2019

Expires

February 22, 2020
Add to Queue


Maximum Credits

0.75 / AMA PRA Category 1 CreditTM

Accredited Provider



This activity is provided by Academy for Continued Healthcare Learning.

Sponsors

This activity is sponsored by Cancer Treatment Centers of America® and ACHL.

Program Description

A multidisciplinary team discusses treatment options for cancer patients in a tumor board format based on data collected from patients, such as, genetic testing, pathology and radiological imaging. Cases discussed include: colon adenocarcinoma, endometrial adenocarcinoma, and breast invasive ductal carcinoma (IDC).

Intended Audience

Physicians or other clinicians who particpate in molecular tumor boards.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Utilize skills learned in this activity to implement an effective molecular tumor board
  • Describe genomic testing and when it is appropriate to test
  • Implement genomic profiling into oncology treatment and select the appropriate patient that is an ideal candidate for profiling

Conflict Of Interest Disclosure Policy

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.

Faculty

Arturo Loaiza-Bonilla, MD, MSEd, FACP
Vice Chair Department of Medical Oncology
Cancer Treatment Centers of America

Dr. Loaiza-Bonilla disclosed that he received consulting fees from Astra Zeneca, PSI CRO, Bayer, Blueprint, Medidata, Taiho, QED, Cardinal Health and FLEX; is on the speaker’s bureau for Celgene, BMS, Caris, Guardant, Eisai, Pfizer and Ipsen; and has ownership interest in Massive Bio.

Bradford Tan, MD
Chair Department of Pathology and Laboratory Medicine
Cancer Treatment Centers of America

Dr. Tan does not have any relevant financial relationships to disclose.

Scott Price, MD
Vice Chair Department of Radiology
Cancer Treatment Centers of America

Dr. Price does not have any relevant financial relationships to disclose.

Pamela Crilley, DO
Chair Department of Medical Oncology
Cancer Treatment Centers of America

Dr. Crilley has no relevant financial relationships to disclose.

Ankur Parikh, DO
Medical Director Precision Medicine
Cancer Treatment Centers of America

Dr. Parikh disclosed that he received consulting fees from Foundation Medicine.

Alan Tan, MD
Medical Director Cancer Research – Phoenix
Cancer Treatment Centers of America

Dr. Tan disclosed that he is on the speaker’s bureau for Bristol Myers Squibb and Astrazeneca.

Maurie Markman, MD
President Medicine & Science
Cancer Treatment Centers of America

Dr. Markman disclosed that he is on the speaker’s bureau for Clovis, Tesaro, Astra-Zeneca and Genentech; and he is on the advisory committee for Merck.

Ricardo Alvarez, MD, MSc
Director Breast Cancer Institute
Cancer Treatment Centers of America

Dr. Alvarez disclosed that he acts as an advisor, reviewer, consultant, speaker and honorarium recipient for Immunomedics, PUMA Biotechnology, and Eisai; is a consultant for R-Pharma; and an honorarium recipient and chair for TTC.

Julian Schink, MD
Chief Division of Gynecological Oncology
Cancer Treatment Centers of America

Dr. Schink does not have any relevant financial relationships to disclose.

Planners Disclosures

The planners for this activity have no relevant financial relationships to disclose. The planning committee includes: Jaci Brown, MEd, Amanda Woodward, RN, Alga Ramos, PharmD, MS, BCPS, Vicki Doctor, BSN, RN, and Sarah Lees, MS, MEd, MHA

Accredited Provider Disclosures

The members of the ACHL team have no relevant financial relationships to disclosure.

Credit

0.75

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Academy for Continued Healthcare Learning (ACHL) and Cancer Treatment Centers of America. ACHL is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Academy of Continued Healthcare Learning designates that this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM  .  Physicians should claim only credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

Disclaimer

Participants have implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information and comparison with recommendations of other authorities.

Instructions

In order to receive credit, participants must complete the pre-assessment questions, post-test, and program evaluation. Participants must also score 65% on the posttest. They may take the test 3 times. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.

For information about the accreditation of this program, please contact Melissa Stradal, mstradal@achlcme.org.

Privacy Policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue


Related to this activity

Dysphagia Palliation in Esophageal Cancer Slide Lecture Series

Dysphagia Palliation in Esophageal Cancer

CME 1.00 Credits